Technology evaluation: ABT-510, Abbott.
ABT-510 is a small peptide thrombospondin-1 mimetic angiogenesis inhibitor under development by Abbott Laboratories for the potential treatment of solid tumors. ABT-510 is undergoing phase II clinical trials.
Radboud University Medical Center, Department of Pathology, PO Box 9101, 6500 HB, Nijmegen, The Netherlands. J.Westphal@obgyn.umcn.nl
Johan R
JR
Westphal
D000595:Amino Acid Sequence; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000235:genetics / Q000378:metabolism* / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000378:metabolism* / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D051379:Mice; D009842:Oligopeptides / Q000009:adverse effects / Q000235:genetics / Q000378:metabolism* / Q000627:therapeutic use; D019700:Thrombospondin 1 / Q000737:chemistry
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; C500617:NAc-Sar-Gly-Val-(d-allo-Ile)-Thr-Nva-Ile-Arg-ProNEt; D009842:Oligopeptides; D019700:Thrombospondin 1